1/ Levo, Neo, Vaso oh my! Many interns worry about understanding these agents of the ICU/CCU. Here is a little #tweetorial #medtweetorial on a fun way to think about them, taught to me by my own senior, the pressor rainbow! Let’s #presstherainbow #medtwitter #MedStudentTwitter
2/ skip to the end for the final diagram, but don't forget as every graduation speech mentions, “Its the not the destination, It's the journey”. Before we start defending the MAP lets first look at the receptors we are going to be manipulating because #physiology is fun!
6/ Let’s round out our receptor talk by mentioning 2 other receptors
Dopamine (D), located in splanchnic and renal circulation, causes vasodilation when activated.
Vasopressin (V1), also found in the peripheral vasculature, causes vasoconstriction when activated
Dopamine (D), located in splanchnic and renal circulation, causes vasodilation when activated.
Vasopressin (V1), also found in the peripheral vasculature, causes vasoconstriction when activated
7/ We got the receptors down but why are they specifically important in the roles of hemodynamic control?
Well it really comes down to two equations:
MAP=CO x SVR
CO=HR x SV
(MAP=Mean arterial pressure, CO=Cardiac Output, SVR=Systemic Vascular Resistance, SV=stroke volume)
Well it really comes down to two equations:
MAP=CO x SVR
CO=HR x SV
(MAP=Mean arterial pressure, CO=Cardiac Output, SVR=Systemic Vascular Resistance, SV=stroke volume)
8/ We can alter these variables by using those receptors we just used above
Activate a1 -> Vasoconstriction -> ⬆️SVR
Activate B1 -> ⬆️HR (chronotropy) and ⬆️SV (inotropy) -> ⬆️CO
Activate B2 -> Vasodilation -> ⬇️SVR
Activate V1 -> Vasoconstriction -> ⬆️SVR
Activate a1 -> Vasoconstriction -> ⬆️SVR
Activate B1 -> ⬆️HR (chronotropy) and ⬆️SV (inotropy) -> ⬆️CO
Activate B2 -> Vasodilation -> ⬇️SVR
Activate V1 -> Vasoconstriction -> ⬆️SVR
9/ Understanding this #physiology we can fit our agents into categories.
1.Inopressors = ↑ inotropy (β1) + vasoconstrict (α1)
2.Inodilators = ↑ inotropy (β1) + vasodilate (β2 or D1)
3.Vasopressors = vasoconstriction (α1 or V1)
Okay time to fill out that #pressorrainbow!
1.Inopressors = ↑ inotropy (β1) + vasoconstrict (α1)
2.Inodilators = ↑ inotropy (β1) + vasodilate (β2 or D1)
3.Vasopressors = vasoconstriction (α1 or V1)
Okay time to fill out that #pressorrainbow!
10/ So starting from the far left of the diagram which of these agents have only alpha activity?
12/ Now moving clockwise on the diagram which of these agents has mainly alpha agonism but also some beta agonism?
15/ Now that we have completed the left side of the rainbow let’s switch it up and start on the far right and then move counterclockwise. So which of these agents has only beta receptor agonism?
18/ finally, Dopamine, an Inoconstrictor
R: B1>D1>a1 (at low-med doses), a1>B1>D1 (at high doses)
Use: symptomatic bradycardia
SE: Tachyarrhymias (Of note, SOAP-II demonstrated increase risk of adverse events compared to norepi in shock treatment)
pubmed.ncbi.nlm.nih.gov
R: B1>D1>a1 (at low-med doses), a1>B1>D1 (at high doses)
Use: symptomatic bradycardia
SE: Tachyarrhymias (Of note, SOAP-II demonstrated increase risk of adverse events compared to norepi in shock treatment)
pubmed.ncbi.nlm.nih.gov
19/ That completes the main rainbow! now you may be wondering what those two blank spots are for? Well, they a for two major agents that don't fall along the rainbow because they don't act on alpha and beta receptors. Those being Vasopressin and Milrinone. Let’s discuss briefly.
20/ Vasopressin, a vassopressor (no way‼️)
R: V1 receptors (⬆️ SVR)
Use: Adjunct to norepi in septic shock, VAATS trial showed in subgroup of patients with less severe septic shock vaso+norepi provided mortality benefit compared to norepi alone
pubmed.ncbi.nlm.nih.gov
R: V1 receptors (⬆️ SVR)
Use: Adjunct to norepi in septic shock, VAATS trial showed in subgroup of patients with less severe septic shock vaso+norepi provided mortality benefit compared to norepi alone
pubmed.ncbi.nlm.nih.gov
22/ so to complete our rainbow
Milrinone, a inodilator and PDE-I (⬆️ CO ⬇️SVR)
Use: Cardiogenic shock, some studies (pubmed.ncbi.nlm.nih.gov) have demonstrated that milrinone ⬇️Pulmonary VR and thus is thought to be beneficial in RH failure
SE: arrhythmogenic
Milrinone, a inodilator and PDE-I (⬆️ CO ⬇️SVR)
Use: Cardiogenic shock, some studies (pubmed.ncbi.nlm.nih.gov) have demonstrated that milrinone ⬇️Pulmonary VR and thus is thought to be beneficial in RH failure
SE: arrhythmogenic
24/ Importance is not to memorize the indications verbatum, but understand the #physiology of these agents. With that understanding as a primer the knowledge and understanding of when to grab what agent will come. So have fun in those ICU/CCUs and get those knowledge reps in 💪
Appreciate any feedback, edits, additions from any and all
@CPSolvers @cardionerds @runthelistpod @rabihmgeha @DxRxEdu @Dr_DanMD @AmitGoyalMD @CarineHamo @heatherkaganmd @thecurbsiders @MedTweetorials @LeivaOrly @WalkerReddM
@CPSolvers @cardionerds @runthelistpod @rabihmgeha @DxRxEdu @Dr_DanMD @AmitGoyalMD @CarineHamo @heatherkaganmd @thecurbsiders @MedTweetorials @LeivaOrly @WalkerReddM
جاري تحميل الاقتراحات...